Gabapentin Capsule
Product Images NDC 68788-8194

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 68788-8194). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Gabapentin Capsules 100mg (F396ec70 826d 45c6 A27c 343c2fac878c 00)

Gabapentin Capsules 100mg (F396ec70 826d 45c6 A27c 343c2fac878c 00)
Gabapentin Capsules 100mg is a medication that is available in capsule form. It is a generic for Neurontin and contains 100mg of Gabapentin in each capsule. The packaging size, expiration date, lot number, batch number, and other manufacturing details are present. The medication needs to be kept at a temperature of 68°-77°F, and excursions to 1553°F are permitted. The capsule is white and imprinted with AHD 100. The directions are available in English, and the medication should be taken as per the doctor's prescription. Federal law prohibits the transfer of this drug to a person other than the patient. The rest of the text seems to be insurance and billing-related information.*
FDA Label Image

Formula (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)

Formula (Ab1e0185 B802 4cf2 A5d4 B71f27f1dcb0 00)
This is a formula for estimating creatinine clearance (CLCr), which is a measure of kidney function. It takes into account the patient's age, weight, and serum creatinine level. The formula is adjusted for female patients by multiplying the result by 0.85. CLCr is important for determining the appropriate dosages of medications that are excreted by the kidneys.*
FDA Label Image

Figure1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 01)

FDA Label Image

Image 1 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 02)

FDA Label Image

Image 2 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)

Image 2 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 03)
This is a chart displaying the mean pain score of individuals over a 4-week fixed dose period. There are three groups being compared: an o-Placsbo group, a Gabapentin 1800 mg/day group, and a Gabapentin 2400 mg/day group. The pain scores were measured at baseline and at seven different time points: weeks 1-5 and then again at weeks 7 and 8.*
FDA Label Image

Image 3 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)

Image 3 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 04)
The text contains a figure showing the proportion of responders with a reduction in pain score of >50% at endpoint for controlled studies on patients with PHN. The figure shows data for Study 1 and Study 2. The text also mentions values of GBP 800 and GBP 2400, however it is unclear what these values are for.*
FDA Label Image

Image 4 (D45f499b 8612 479e 8dd2 4fe28b1f5f9c 05)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.